# Study of GS-1219 in Participants With HIV-1

> **NCT07115368** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 4 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** GS-1219
- **DRUG:** BVY
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT07115368
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-08-11
- **Primary completion:** 2025-09-19
- **Final completion:** 2025-10-02
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate study.
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07115368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07115368, "Study of GS-1219 in Participants With HIV-1". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07115368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*